Cantor Fitzgerald initiated coverage of Tempus AI, Inc. with an overweight rating.
The firm set a price target of $80.00 for the company.
Analysts believe the market currently undervalues the Data & Applications segment.
Cantor argues the margin profile resembles a high-value platform business rather than a standard life sciences vendor.
This outlook follows recent adjustments from other analysts.
H.C. Wainwright recently lowered its price target to $56.
BTIG adjusted its target to $70 following second-quarter financial results.
Cantor highlights the company’s strategic positioning in AI-powered precision medicine.